The Snell's waltzer mouse (Myo6 sv/sv ) serves as a model for human deafness and vestibular behavioral impairment, caused by a spontaneous 130 bp recessive deletion in the Myo6 gene. In this study, we characterized the auditory and vestibular phenotypes of Myo6 sv/sv mice....
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is preclinical animal research; while promising for the gene therapy pipeline, findings cannot be applied to clinical practice until human trials are completed.
Validating gene therapy in a well-characterised mouse model of Myo6-related deafness advances the translational pipeline toward potential treatments for a genetic form of human hearing loss and vestibular dysfunction.
- 01Snell's waltzer mice (Myo6 sv/sv) serve as a model for recessive Myo6-linked human deafness and balance problems.
- 02Study systematically assessed both auditory and vestibular function in this model.
- 03Gene therapy targeting the Myo6 deletion was evaluated for restoration of hearing and balance.
- 04Research published in Mammalian Genome (DOI: 10.1007/s00335-026-10263-y).
- 05Findings are preclinical and limited to an animal model at this stage.
The Snell's waltzer mouse (Myo6 sv/sv) is a valid model of human deafness and balance dysfunction caused by recessive Myo6 gene deletion.
studysupportedGene therapy can be evaluated for restoration of auditory and vestibular function in the Snell's waltzer mouse model.
studypartially supported- PMID
- 42665733
- DOI
- 10.1007/s00335-026-10263-y.
- Journal
- Mammalian Genome
- Publication type
- research_article
- Evidence level
- 4
- Population
- Snell's waltzer mice (Myo6 sv/sv), a recessive mouse model of human genetic deafness and vestibular dysfunction
- Intervention
- Gene therapy targeting the Myo6 gene deletion
Primary outcomes
Auditory function (e.g., ABR thresholds or equivalent measures); Vestibular function assessment; Efficacy of gene therapy in restoring hearing and balance